Tenor Capital Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Tenor Capital Management’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100,000	Closed	-$1.01M	–	595
2022 Q4	$1.01M	Hold	100,000	–	–	0.02%	285
2022 Q3	$991K	Hold	100,000	–	–	0.02%	377
2022 Q2	$979K	Hold	100,000	–	–	0.02%	399
2022 Q1	$974K	Hold	100,000	–	–	0.02%	425
2021 Q4	$969K	Hold	100,000	–	–	0.02%	429
2021 Q3	$967K	Hold	100,000	–	–	0.02%	376
2021 Q2	$974K	Buy	+100,000	New	+$982K	0.02%	372

Tenor Capital Management's EBAC Position: Q1 2023 in Review

Tenor Capital Management sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 100,000 shares — an estimated $1.01M sold.

Tenor Capital Management first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $1.01M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Tenor Capital Management reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Tenor Capital Management sold 100,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $1.01M.
Tenor Capital Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Tenor Capital Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $1.01M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Tenor Capital Management's 13F filing for Q1 2023, filed 15 May 2023.